Loading Events

VIRTUAL MEETING – 13th April 2022

sorry this event is now complete but you can find the webinars/ presentations in the members hub

Overview

Following our successful industrial insights events in April 2021 and September 2021, we will be holding another event on the 13th of April 2022.

Speakers and Chairs

Benjamin Gabriele
Senior Particle Scientist, AstraZeneca

Professor Hannah Batchelor
Strathclyde Institute of Pharmacy and Biomedical Sciences

Dr Mridul Majumder
BPharm MPharm MSc PhD FRSC MAPS, Founder and Director M2M Pharmaceuticals Limited

Kieran Sproston
Formulation Scientist, Drug Product Design, Pfizer

Programme

13th April 2022 – 13.00-17.00 UK Time/14.00-18.00 CET

 

1300 hours – Welcome – NSFG Committee

1310 hours – Keynote Speaker – Hannah Batchelor, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde)

1340 hours – Career Journeys – short presentations and Q&A:

Benjamin Gabriel, Senior Particle Scientist, AstraZeneca

Kieran Sproston, Formulation Scientist, Drug Product Design, Pfizer

1420 hours – Video Session – Working for a Pharmaceutical start-up (FabRx, UCL)

1440 hours – Break

1500 hours – Keynote Speaker – Mridul Majumber, Founder and Director M2M Pharmaceuticals Limited

1530 hours – Interactive Session – Virtual Manufacturing Plant Tour – Mohammed Babar, Campaign Manager and Process Chemist In The Large Scale Laboratory, Early Chemical Development, AstraZeneca

1615 hours – Pharmacetutical Question Time – a chance to ask questions on careers in the Pharmaceutical Industry

1655 hours – Wrap-up – NSFG Committee

1700 hours – Close

Career Journeys speakers:
Benjamin Gabriele
Senior Particle Scientist, AstraZeneca
Bio:

Benjamin Gabriele obtained in 2015 his MEng in Materials Science from the National Institute of Applied Sciences (INSA) of Lyon in France. In 2016, he started a PhD with Dr Aurora Cruz-Cabeza in the Department of Chemical Engineering & Analytical Science at the University of Manchester. His focus was on the crystallisation and the characterisation of organic single crystals. His work included many aspects of crystallisation and material sciences such as polymorphism and mechanical properties of single crystals. As a result, he also worked in close collaboration with Prof. Brian Derby from the Department of Materials at the University of Manchester. He successfully graduated at the end of 2020. He then started a new role as a Particle Scientist at Concept Life Sciences before joining AstraZeneca for a similar role from March 2021. His interest lies in the characterisation of organic compounds and how their properties correlate with single crystal data.

Professor Hannah Batchelor

Strathclyde Institute of Pharmacy and Biomedical Sciences

161 Cathedral Street

Glasgow G4 0RE

hannah.batchelor@strath.ac.uk

https://pureportal.strath.ac.uk/en/persons/hannah-batchelor

www.strath.ac.uk/sipbs

Twitter @han_batchelor

ORCID ID 0000-0002-8729-9951

Personal webpage: www.hannahbatchelor.com

TEDx Talk: https://www.youtube.com/watch?v=DGbqLsY5J4c.

Biography:

Professor Hannah Batchelor is a pharmaceutical scientist who has worked in academia, the NHS and within pharmaceutical industry. She is currently based at the Strathclyde Institute of Pharmacy and Biomedical Science, University of Strathclyde in Glasgow.

She works on the design and manipulation of medicines to create age appropriate drug formulations to maximise clinical efficacy in paediatric patients. Her research interests lie in the optimisation of drug formulations to maximise their biopharmaceutical performance and acceptability to children. Her research is informed by the views of children, young people and parents to ensure that the patients are at the centre of new developments.

Hannah is the current chair of the Academy of Pharmaceutical Sciences in the UK. She is still passionate about pharmaceutical sciences and is motivated to inspire the next generation of scientists.

Dr Mridul Majumder
BPharm MPharm MSc PhD FRSC MAPS, Founder and Director M2M Pharmaceuticals Limited.

About: 

Dr Mridul Majumder is a Pharmaceutical scientist with a PhD in Pharmaceutics. Founder and Director of M2M Pharmaceuticals Ltd since 2016. In past, worked for a CRO for 12 years in early stage product development especially related to material science for inhaled drug delivery. Have worked in principles to cGMP as per the ICH Q8, Q9, Q10 and Q11.

Special Interests:

Amorphous materials (intentional/unintentional) Amorphous content determination with method development and validation Inhalation drug delivery
Solid form selection Batch-to-batch variability
Solid dispersion Co-crystallisation in solid-state.

Contact Details:

The Gateway Building
1 Collegiate Square
Thames Valley Science Park (TVSP) Reading RG2 9LH
UK
T: + 44 (0) 118 304 1035 (direct)
T: + 44 (0) 118 304 1002 (switch)
M: + 44 (0) 7946 560263
E: mridul.majumder@m2mpharma.com E: info@m2mpharma.com
W: www.m2mpharma.com

Kieran Sproston

Formulation Scientist, Drug Product Design, Pfizer

Kieran is a Formulation Scientist working in Pfizer to develop the formulation and manufacturing process for some of their novel compounds.  He is from a Pharmacy background, graduating from University of Manchester in 2019. He completed his pre-registration year split between Paydens Community Pharmacy and Pfizer and has continued in the same department since then.
Babar Mohammed, Campaign Manager and Process Chemist In The Large Scale Laboratory, Early Chemical Development, AstraZeneca.

’Mohammad Babar obtained his MChem from the University of Liverpool in 2017. He then joined the Analytical & Science Technology department at Novartis focussing on GMP (Good Manufacturing Practice). In 2018, he joined Manchester Organics Ltd. as a Synthetic Organic Chemist working on route design, process development and the scale up of primarily organofluoride compounds. Since 2019, Mohammad has held various roles at AstraZeneca, currently working flexibly between Process Chemistry and the Large Scale Laboratory within Early Chemical Development at Macclesfield, UK. His key responsibilities involve developing robust processes of key intermediates & APIs, whilst also planning the accommodation of GMP drug substance manufactures.’’